A novel inflammatory marker for incident coronary heart disease

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 34, Issue 12, 2014, Pages 2695-2699

  Ligthart, Symen ^a   Sedaghat, Sanaz ^a   Arfan Ikram, M ^a   Hofman, Albert ^a   Franco, Oscar H ^a   Dehghan, Abbas ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Biomarker; Coronary artery disease; Cytokines; Inflammation

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; ANTIHYPERTENSIVE AGENT; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CD40 LIGAND; COMPLEMENT COMPONENT C3; INTERLEUKIN 18; INTERLEUKIN 8; MACROPHAGE MIGRATION INHIBITION FACTOR; MONOCYTE CHEMOTACTIC PROTEIN; AUTACOID; PROTEIN S 100; S100A12 PROTEIN, HUMAN;

AGED; ARTICLE; CARDIOVASCULAR RISK; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE MARKER; FEMALE; FOLLOW UP; HAZARD RATIO; HUMAN; ISCHEMIC HEART DISEASE; KIDNEY DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; POPULATION RESEARCH; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; BLOOD; COHORT ANALYSIS; CORONARY DISEASE; INCIDENCE; MORTALITY; MULTIVARIATE ANALYSIS; NETHERLANDS; PROPORTIONAL HAZARDS MODEL; RISK FACTOR; VERY ELDERLY;

AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; COHORT STUDIES; CORONARY DISEASE; FEMALE; HUMANS; INCIDENCE; INFLAMMATION MEDIATORS; MALE; MULTIVARIATE ANALYSIS; NETHERLANDS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RISK FACTORS; S100 PROTEINS;

EID: 84918826265     PISSN: 10795642     EISSN: 15244636     Source Type: Journal    
DOI: 10.1161/ATVBAHA.114.304306     Document Type: Article

References (29)

1. Alwan A. Global Status Report on Noncommunicable Diseases 2010. World Health Organization; 2011.
2. Libby P. Inflammation in atherosclerosis. Arterioscler Thromb Vasc Biol. 2012;32:2045-2051.
3. Danesh J, Wheeler JG, Hirschfield GM, Eda S, Eiriksdottir G, Rumley A, Lowe GD, Pepys MB, Gudnason V. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med. 2004;350:1387-1397.
4. Danesh J, Kaptoge S, Mann AG, Sarwar N, Wood A, Angleman SB, Wensley F, Higgins JP, Lennon L, Eiriksdottir G, Rumley A, Whincup PH, Lowe GD, Gudnason V. Long-term interleukin-6 levels and subsequent risk of coronary heart disease: two new prospective studies and a systematic review. PLoS Med. 2008;5:e78.
5. Pai JK, Pischon T, Ma J, Manson JE, Hankinson SE, Joshipura K, Curhan GC, Rifai N, Cannuscio CC, Stampfer MJ, Rimm EB. Inflammatory markers and the risk of coronary heart disease in men and women. N Engl J Med. 2004;351:2599-2610.
6. Kaptoge S, Seshasai SRK, Gao P, Freitag DF, Butterworth AS, Borglykke A, Di Angelantonio E, Gudnason V, Rumley A, Lowe GDO. Inflammatory cytokines and risk of coronary heart disease: new prospective study and updated meta-analysis. Eur Heart J. 2013:eht367.
7. Hansson GK, Hermansson A. The immune system in atherosclerosis. Nat Immunol. 2011;12:204-212.
8. Foell D, Kucharzik T, Kraft M, Vogl T, Sorg C, Domschke W, Roth J. Neutrophil derived human S100A12 (EN-R.A.GE) is strongly expressed during chronic active inflammatory bowel disease. Gut. 2003;52:847-853.
9. Kosaki A, Hasegawa T, Kimura T, Iida K, Hitomi J, Matsubara H, Mori Y, Okigaki M, Toyoda N, Masaki H, Inoue-Shibata M, Nishikawa M, Iwasaka T. Increased plasma S100A12 (EN-R.A.GE) levels in patients with type 2 diabetes. J Clin Endocrinol Metab. 2004;89:5423-5428.
10. Mori Y, Kosaki A, Kishimoto N, Kimura T, Iida K, Fukui M, Nakajima F, Nagahara M, Urakami M, Iwasaka T, Matsubara H. Increased plasma S100A12 (EN-R.A.GE) levels in hemodialysis patients with atherosclerosis. Am J Nephrol. 2009;29:18-24.
11. Shiotsu Y, Mori Y, Nishimura M, Sakoda C, Tokoro T, Hatta T, Maki N, Iida K, Iwamoto N, Ono T, Matsuoka E, Kishimoto N, Tamagaki K, Matsubara H, Kosaki A. Plasma S100A12 level is associated with cardiovascular disease in hemodialysis patients. Clin J Am Soc Nephrol. 2011;6:718-723.
12. Tydén H, Lood C, Gullstrand B, Jönsen A, Nived O, Sturfelt G, Truedsson L, Ivars F, Leanderson T, Bengtsson AA. Increased serum levels of S100A8/A9 and S100A12 are associated with cardiovascular disease in patients with inactive systemic lupus erythematosus. Rheumatology (Oxford). 2013;52:2048-2055.
13. Rosenberg S, Elashoff MR, Beineke P, et al; PREDICT (Personalized Risk Evaluation and Diagnosis in the Coronary Tree) Investigators. Multicenter validation of the diagnostic accuracy of a blood-based gene expression test for assessing obstructive coronary artery disease in nondiabetic patients. Ann Intern Med. 2010;153:425-434.
14. Zhao P, Wu M, Yu H, Huang Y, Wang Y, Wang W, Yin W. Serum S100A12 levels are correlated with the presence and severity of coronary artery disease in patients with type 2 diabetes mellitus. J Investig Med. 2013;61:861-866.
15. Mahajan N, Malik N, Bahl A, Dhawan V. Receptor for advanced glycation end products (R.A.GE) and its inflammatory ligand EN-R.A.GE in nondiabetic subjects with pre-mature coronary artery disease. Atherosclerosis. 2009;207:597-602.
16. Liu J, Ren YG, Zhang LH, Tong YW, Kang L. Serum S100A12 concentrations are correlated with angiographic coronary lesion complexity in patients with coronary artery disease. Scand J Clin Lab Invest. 2014;74:149-154.
17. Nakashima A, Carrero JJ, Qureshi AR, Miyamoto T, Anderstam B, Bárány P, Heimbürger O, Stenvinkel P, Lindholm B. Effect of circulating soluble receptor for advanced glycation end products (sR.A.GE) and the proinflammatory R.A.GE ligand (EN-R.A.GE, S100A12) on mortality in hemodialysis patients. Clin J Am Soc Nephrol. 2010;5:2213-2219.
18. Saito T, Hojo Y, Ogoyama Y, Hirose M, Ikemoto T, Katsuki T, Shimada K, Kario K. S100A12 as a marker to predict cardiovascular events in patients with chronic coronary artery disease. Circ J. 2012;76:2647-2652.
19. Healy AM, Pickard MD, Pradhan AD, et al. Platelet expression profiling and clinical validation of myeloid-related protein-14 as a novel determinant of cardiovascular events. Circulation. 2006;113:2278-2284.
20. Burke AP, Kolodgie FD, Zieske A, Fowler DR, Weber DK, Varghese PJ, Farb A, Virmani R. Morphologic findings of coronary atherosclerotic plaques in diabetics a postmortem study. Arterioscler Thromb Vasc Biol. 2004;24:1266-1271.
21. Hofmann M.A., Drury S, Fu C, et al. R.A.GE mediates a novel proinflammatory axis: a central cell surface receptor for S100/calgranulin polypeptides. Cell. 1999;97:889-901.
22. Foell D, Wittkowski H, Kessel C, Lüken A, Weinhage T, Varga G, Vogl T, Wirth T, Viemann D, Björk P. Pro-inflammatory S100A12 can Activate Human Monocytes via Toll-like Receptor 4. Am J Respir Crit Care Med. 2013;187:1324-1334.
23. Brett J, Schmidt AM, Yan SD, Zou YS, Weidman E, Pinsky D, Nowygrod R, Neeper M, Przysiecki C, Shaw A. Survey of the distribution of a newly characterized receptor for advanced glycation end products in tissues. Am J Pathol. 1993;143:1699-1712.
24. Hansson GK, Libby P, Schönbeck U, Yan ZQ. Innate and adaptive immunity in the pathogenesis of atherosclerosis. Circ Res. 2002;91:281-291.
25. Hofmann Bowman M, Wilk J, Heydemann A, Kim G, Rehman J, Lodato JA, Raman J, McNally EM. S100A12 mediates aortic wall remodeling and aortic aneurysm. Circ Res. 2010;106:145-154.
26. Bowman M.A.H, Gawdzik J, Bukhari U, Husain AN, Toth PT, Kim G, Earley J, McNally EM. S100A12 in vascular smooth muscle accelerates vascular calcification in apolipoprotein E-null mice by activating an osteogenic gene regulatory program. Arterioscler Thromb Vasc Biol. 2011;31:337-344.
27. Yan L, Mathew L, Chellan B, Gardner B, Earley J, Puri TS, Bowman M.A.H. S100/Calgranulin-mediated inflammation accelerates left ventricular hypertrophy and aortic valve sclerosis in chronic kidney disease in a receptor for advanced glycation end products-dependent manner. Arterioscler Thromb Vasc Biol. 2014;34:1399-1411.
28. Frantz S, Ertl G, Bauersachs J. Mechanisms of disease: Toll-like receptors in cardiovascular disease. Nat Clin Pract Cardiovasc Med. 2007;4:444-454.
29. Yan L, Bjork P, Butuc R, Gawdzik J, Earley J, Kim G, Hofmann Bowman M.A. Beneficial effects of quinoline-3-carboxamide (ABR-215757) on atherosclerotic plaque morphology in S100A12 transgenic ApoE null mice. Atherosclerosis. 2013;228:69-79.